12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AS1411: Phase IIb discontinued

Antisoma discontinued an open-label, international Phase IIb trial of AS1411 after early data from about 45 patients showed that the compound was unlikely to show a clear benefit. The company said it will focus on preclinical studies of the anti-nucleolin aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc.,...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >